5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. - Wikidata - wikimedia - TriplyDB

5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.

5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.

http://www.wikidata.org/entity/Q34777582

about

Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease Epigenetics of colorectal cancer Epigenetic therapy in gastrointestinal cancer: the right combination Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies Serrated polyps of right colon: guilty or innocent?The more the messier: centrosome amplification as a novel biomarker for personalized treatment of colorectal cancers Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG Island Methylator phenotype Functional Characterization and Drug Response of Freshly Established Patient-Derived Tumor Models with CpG Island Methylator Phenotype Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter The CpG island methylator phenotype (CIMP) in colorectal cancer.CpG island methylator phenotype and its association with malignancy in sporadic duodenal adenomas.Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years IGFBP3 methylation is a novel diagnostic and predictive biomarker in colorectal cancer.CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.CpG island methylator phenotype and prognosis of colorectal cancer in Northeast China.A CpG island methylator phenotype of colorectal cancer that is contiguous with conventional adenomas, but not serrated polyps.The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer.Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers.Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis.Association between molecular subtypes of colorectal cancer and patient survival DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.Identification of subgroup-specific miRNA patterns by epigenetic profiling of sporadic and Lynch syndrome-associated colorectal and endometrial carcinoma.Fusobacterium in colonic flora and molecular features of colorectal carcinoma.Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy.Choosing the optimal method in programmatic colorectal cancer screening: current evidence and controversies.Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results.Tracking the Correlation Between CpG Island Methylator Phenotype and Other Molecular Features and Clinicopathological Features in Human Colorectal Cancers: A Systematic Review and Meta-Analysis.Stratification and Prognostic Relevance of Jass's Molecular Classification of Colorectal Cancer.CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer.Epigenetics and colorectal cancer One colon lumen but two organs.How many diseases are colorectal cancer?Characterization of CDKN2A(p16) methylation and impact in colorectal cancer: systematic analysis using pyrosequencing.Targeted therapies in colorectal cancer-an integrative view by PPPM Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision.

P2860

Q24289344-49FC2F15-2189-43B4-9130-1E34DBF32D06 Q24598045-B9B4EC6E-10A0-4FF0-AD41-065ABD2DA57B Q26745709-B7F1A319-ABD2-4DC6-AD64-BB2F921B10A5 Q26751035-5E6C987E-1C25-4C1A-B304-9CFB18661681 Q26768471-791A7CC3-F01A-44B1-839C-CB920AD1F9B4 Q26772276-938E13E1-C31F-47A4-907B-D126D67B3E3B Q27025004-AB9A2F8D-42D7-4A2C-B8EC-4C075080D192 Q28072910-35FBDA4E-C996-4972-AB2C-48566BBF8760 Q28084346-F95DA6B9-8D47-4BF3-8A1B-95FEF881C664 Q28247866-79C3B194-E425-451E-9741-A9E3C4940F63 Q28551197-4E5B5D67-D71F-4AB8-AD28-85442B76C167 Q30276647-4408E6B6-7C1E-4731-A2F7-8A76C777D09E Q33596629-609EAF76-2919-44F8-B87E-37514E24B779 Q33779182-7438C432-73A0-4E06-A84B-1E15B18ECAFC Q34008793-DC24F672-40ED-4AD2-8228-561819046B9C Q34050656-ABF665D2-3B74-40E1-A37E-552D8252C376 Q34084652-9A8A0164-3EF0-4558-92DC-13D6B72415C5 Q34177058-F20C2352-5E00-4307-BEA3-F10290B16B42 Q34293192-D53D9C05-956F-4979-A549-5FF7AEFB5D17 Q34441849-F9875A8D-5D82-4370-ADB9-7E0F6FBC7F30 Q34487177-ADBD0205-88E8-4752-BBDA-71F6069143D5 Q34553646-F44078AF-1371-423E-B9E0-EC8A8C8C475F Q34759064-B31ED367-6BF5-4CA4-907E-C651C900290A Q35031411-F0512085-E48F-4B31-89C1-636678918B0B Q35169860-9006C750-7CA3-438F-B9ED-3AA89763216A Q35404536-05362BC7-CC15-4F42-BF77-919B4299193F Q35721124-BAC5153C-DFA6-49C3-844F-FAE550BBE9A2 Q35773077-B4EA7E8C-BA62-45C0-B28D-4ED39A08FBA2 Q35780915-0CA828C1-1490-494B-9007-4BDAA6EB246B Q35836592-B6EB8FA9-ABB8-4406-AA57-4EA8C518E786 Q35925275-C1B50DF5-A5B2-4136-967E-5E29B18D2258 Q35952149-587F17D9-BAE0-4805-A55D-B19F7E98F04A Q35971768-EAE71D14-F83B-40A3-AC84-0FF10D171784 Q36075933-CF685B9B-D87C-42DB-A737-CA97145D08E7 Q36081553-F586EC9F-7D2A-41C5-A236-AAF29687C293 Q36179345-B60FF114-7F30-4F2C-A8BF-EB4731A25814 Q36238965-5AF1D441-44B5-4DBF-9226-20ED5E92A9A8 Q36341102-00406004-BF15-41BC-9C50-1A7F5597A9FA Q36646911-189D3051-BBC5-4296-A7FA-D4BE02129E17 Q36688767-C6DD120E-32CC-43FA-AB76-3E03CF95E0BA

P2860

5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.

http://www.wikidata.org/entity/Q34777582

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

5-Fluorouracil adjuvant chemot ...... r phenotype colorectal cancer.

@ast

5-Fluorouracil adjuvant chemot ...... r phenotype colorectal cancer.

@en

5-Fluorouracil adjuvant chemot ...... r phenotype colorectal cancer.

@nl

type

label

5-Fluorouracil adjuvant chemot ...... r phenotype colorectal cancer.

@ast

5-Fluorouracil adjuvant chemot ...... r phenotype colorectal cancer.

@en

5-Fluorouracil adjuvant chemot ...... r phenotype colorectal cancer.

@nl

prefLabel

5-Fluorouracil adjuvant chemot ...... r phenotype colorectal cancer.

@ast

5-Fluorouracil adjuvant chemot ...... r phenotype colorectal cancer.

@en

5-Fluorouracil adjuvant chemot ...... r phenotype colorectal cancer.

@nl

P1433

Q34777582-DD81D4A6-324F-4AB7-93D9-4BD049E360DB

P1476

Q34777582-69D7A50C-9EC5-4D39-AD97-CE270B534C7D

P2093

Q34777582-2151A6DA-5196-45E5-BD8C-23460DB20252

Q34777582-437641C7-5D2C-4E9B-9C80-BABABD55B49A

Q34777582-4EDB6E96-154C-4C6C-A8AE-8626744589B5

Q34777582-65C016B1-0C1C-4AEA-8F8C-D66B68A49DB7

Q34777582-764F0B7A-DBBB-4A32-9F4D-BF78A5B74B9F

Q34777582-7CE804B3-991A-4009-B17F-E9A0FE485223

Q34777582-861C65E7-4855-4381-A7A4-379C4760946C

Q34777582-A5819AF9-34D4-455C-BF1A-0AAAB442F8DF

Q34777582-AC08B393-BB40-4BF3-881E-D9FBE390595F

Q34777582-B1803E09-97FF-4BD2-A7B1-F28C56AEF90A

P2860

Q34777582-0218E3AD-26FE-4CD9-8FFB-7EFFC03784E4

Q34777582-16454A2A-2F0A-4898-A3B1-E1AFB8C4BBA4

Q34777582-16A735D6-7C1D-44EF-B387-807E004394EE

Q34777582-24B3CE23-F4DC-4CD2-A270-29102151BC11

Q34777582-2648AF54-CDC4-44D3-981E-E335A5721EFC

Q34777582-2755A6C2-E6AC-42D6-AE26-F400497B784F

Q34777582-3E3FD40F-50EB-4F25-8FCC-51C84A7A4A39

Q34777582-459D414F-91CE-4D4A-B476-E327B4803425

Q34777582-465EA4D0-6144-4967-865A-6D12FF3E386E

Q34777582-4EC01AA3-8EDD-49B6-A04E-BFB11FD71093

P304

Q34777582-BC98A3C1-E3CD-4FE0-8CB8-7285A79923CA

P31

Q34777582-B782EFE4-79D0-4C11-9D62-F2D8EAF707D9

P356

Q34777582-DDE574C9-1AAA-4CC3-A054-4454AA19DDE1

P407

Q34777582-F18DFB61-4CE8-4BD5-8C4B-81F5697B56D7

P433

Q34777582-B5346CB0-A7FA-4FC9-BC76-126E3A6DD698

P478

Q34777582-0C8FDAA2-462D-428A-AE9F-83C8CEA9B9C5

P50

Q34777582-369E07F4-26BA-4876-AC5B-2037926BDFBF

Q34777582-48041927-73AD-478A-ADAC-A9A488869EF5

Q34777582-48178811-C840-4BFE-B91A-16E9C04930E6

Q34777582-89B95EB7-0DED-4C7D-8487-919E1866F57E

Q34777582-93730E08-FC32-43C4-B6F2-969344505F0B

P577

Q34777582-0A46B39E-03BA-4446-BE9D-2A164A69B868

P5875

Q34777582-A79D7720-0403-46B7-999A-8378E69293D7

P698

Q34777582-BD0E087B-AE2B-4DDE-9ACE-B63E5FFE4369

P921

Q34777582-338B5D99-CB42-40FC-997B-4B75A0B24DA8

Q34777582-9DC5E1C5-38F2-4A71-A55E-905FD9294AA4

P932

Q34777582-D1866345-B84A-4B20-B47F-999861ED5002

P356

J.GASTRO.2010.12.035

P1433

Gastroenterology

P1476

5-Fluorouracil adjuvant chemot ...... or phenotype colorectal cancer

@en

P2093

Artemio Payá

http://www.w3.org/2001/XMLSchema#string

C Richard Boland

http://www.w3.org/2001/XMLSchema#string

Cristina Alenda

http://www.w3.org/2001/XMLSchema#string

David Nicolás-Pérez

http://www.w3.org/2001/XMLSchema#string

Estefanía Rojas

http://www.w3.org/2001/XMLSchema#string

Francesc Balaguer

http://www.w3.org/2001/XMLSchema#string

Josep M Reñé

http://www.w3.org/2001/XMLSchema#string

Juan Clofent

http://www.w3.org/2001/XMLSchema#string

Juan D Morillas

http://www.w3.org/2001/XMLSchema#string

Lucía Pérez-Carbonell

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer

Microsatellite instability in colorectal cancer

Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology

A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer

Systematic review of microsatellite instability and colorectal cancer prognosis

Epigenetics in human disease and prospects for epigenetic therapy

CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer

Gene silencing in cancer in association with promoter hypermethylation

Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines

An optimized pentaplex PCR for detecting DNA mismatch repair-deficient colorectal cancers

P304

1174-1181

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.GASTRO.2010.12.035

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

140

http://www.w3.org/2001/XMLSchema#string

P50

Antoni Castells

Joaquín Cubiella

P577

2010-12-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49709414

http://www.w3.org/2001/XMLSchema#string

P698

21185836

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

3073650

http://www.w3.org/2001/XMLSchema#string